Advanced Dedifferentiated Liposarcoma clinical trials

Explore recruiting advanced dedifferentiated liposarcoma clinical trials.

Recruiting advanced dedifferentiated liposarcoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Dedifferentiated Liposarcoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma

Netherlands, Belgium, Czechia, Portugal, Spain, Norway +6 more

Phase II and Phase III (Integrated) EU CTIS Study details

PERELI - A phase 2, open label study of PEmigatinib and REtifanlimab in advanced dedifferentiated Liposarcoma

Sweden, Norway, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naïve or pre-treated advanced dedifferentiated liposarcoma

Belgium, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Advanced Dedifferentiated Liposarcoma trials by city

Advanced Dedifferentiated Liposarcoma clinical trials

Recruiting advanced dedifferentiated liposarcoma studies right now

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma

A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

Also recruiting in Europe

Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma

PERELI - A phase 2, open label study of PEmigatinib and REtifanlimab in advanced dedifferentiated Liposarcoma

Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naïve or pre-treated advanced dedifferentiated liposarcoma

Advanced Dedifferentiated Liposarcoma trials by city

Other conditions